- Research article
- Open Access
- Open Peer Review
Pirfenidone inhibits TGF-β1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells
BMC Pulmonary Medicinevolume 12, Article number: 24 (2012)
Pirfenidone is a novel anti-fibrotic and anti-inflammatory agent that inhibits the progression of fibrosis in animal models and in patients with idiopathic pulmonary fibrosis (IPF). We previously showed that pirfenidone inhibits the over-expression of collagen type I and of heat shock protein (HSP) 47, a collagen-specific molecular chaperone, in human lung fibroblasts stimulated with transforming growth factor (TGF)-β1 in vitro. The increased numbers of HSP47-positive type II pneumocytes as well as fibroblasts were also diminished by pirfenidone in an animal model of pulmonary fibrosis induced by bleomycin. The present study evaluates the effects of pirfenidone on collagen type I and HSP47 expression in the human alveolar epithelial cell line, A549 cells in vitro.
The expression of collagen type I, HSP47 and E-cadherin mRNAs in A549 cells stimulated with TGF-β1 was evaluated by Northern blotting or real-time PCR. The expression of collagen type I, HSP47 and fibronectin proteins was assessed by immunocytochemical staining.
TGF-β1 stimulated collagen type I and HSP47 mRNA and protein expression in A549 cells, and pirfenidone significantly inhibited this process. Pirfenidone also inhibited over-expression of the fibroblast phenotypic marker fibronectin in A549 cells induced by TGF-β1.
We concluded that the anti-fibrotic effects of pirfenidone might be mediated not only through the direct inhibition of collagen type I expression but also through the inhibition of HSP47 expression in alveolar epithelial cells, which results in reduced collagen synthesis in lung fibrosis. Furthermore, pirfenidone might partially inhibit the epithelial-mesenchymal transition.
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disorder characterized by patchy fibrotic areas with fibroblast proliferation and extracellular matrix remodeling that results in irreversible distortion of the lung architecture. The underlying molecular mechanisms through which excessive collagen is deposited in fibrotic lesions are not fully understood. The pathological features of IPF include scattered fibroblast foci that consist of aggregates of mesenchymal cells, and which are associated with the progression of fibrosis . Although resident fibroblasts probably expand in response to injury, recent studies support the notion that lung fibroblast development might also be derived from bone marrow and/or epithelial cells . The alveolar epithelial to mesenchymal transition (EMT) has been studied in detail from the viewpoint of the pathogenesis of lung, as well as renal fibrosis [2–5]. Alveolar epithelial cells are also the primary source of mediators such as platelet-derived growth factor, transforming growth factor (TGF)-β1, tumor necrosis factor (TNF)-α and connective tissue growth factor that can induce fibroblast migration, proliferation and activation . Thus, alveolar epithelial cells as well as fibroblasts are important in the pathogenesis of lung fibrosis.
Pirfenidone is a novel antifibrotic agent that inhibits the progression of lung, kidney and hepatic fibrosis in experimental models [7–13]. This drug also exerts anti-inflammatory properties including the regulation of key growth factors and cytokines [10, 11, 14–16], and recent clinical trials have revealed its therapeutic effects in patients with IPF [17–19]. However, the exact mechanisms through which pirfenidone offers protection against lung fibrosis remain unclear. In this context, we recently found that pirfenidone inhibits the expression of collagen type I and heat shock protein (HSP) 47, a collagen-specific molecular chaperone, in TGF-β-stimulated human lung fibroblasts in vitro. Using a mouse model of bleomycin-induced pulmonary fibrosis, we also discovered that pirfenidone inhibits HSP47 over-expression in myofibroblasts and in type II pneumocytes, especially in fibrotic lesions, and that this activity is concomitant with an obvious reduction in fibrosis . HSP47 is localized in the endoplasmic reticulum that participates in the intracellular processing, folding, assembly and secretion of procollagens [21–23]. Irrespective of the tissue site and organ, HSP47 expression is always induced during the process of fibrosis, particularly in and around fibrotic lesions [12, 24, 25]. Therefore, HSP47-positive cells, especially myofibroblasts, might play a central role in the synthesis, deposition and remodeling of the ECM in pulmonary fibrosis in both patients and in animal models [12, 26, 27]. In this context, collagen type I and HSP47 expression is recently considered to be one of the useful parameters for recognizing EMT . However, the specific effects of pirfenidone upon collagen and HSP47 synthesis and EMT in alveolar epithelial cells in vitro remain obscure.
To clarify the association between alveolar epithelial cells and lung fibrosis and the action of pirfenidone in vitro, we examined the expression of collagen type I and HSP47 in the human alveolar epithelial cell line, A549, stimulated with TGF-β1.
Materials and methods
Cells and Reagents
The human type II alveolar epithelial cell line, A549 (The American Type Culture Collection, Manassas, VA), was maintained in Dulbecco's modified minimal essential medium (DMEM) containing 10% FBS and 2 mM L-glutamine at 37 °C in a 5% CO2-humidified atmosphere. All experiments proceeded using cells after 3–5 cell passages. Pirfenidone was provided by Shionogi & Co., Ltd (Osaka, Japan). Recombinant human TGF-β1 (R&D Systems, Inc. Minneapolis, MN), was reconstituted in 4 mM HCl containing 0.1% bovine serum albumin (BSA) to prepare a 1 μg/ml stock solution of active growth factor. The stock solution was added to media to yield various final concentrations of TGF-β1. To control for nonspecific effects, cells were incubated in an equal volume of 4 mM HCl and BSA solution was added to the basal media.
Incubation of cells with pirfenidone and TGF-β1
Subcultures of A549 cells were seeded in 60-mm culture dishes (BD FalconTM, Franklin Lakes, NJ) at a density of 1 × 105 per dish to analyze collagen type I and HSP47 mRNA expression and protein levels. When the cells reached 70 - 80% confluence, the medium was replaced with serum-free DMEM. The cells were subsequently stimulated for 3, 6, 12, 24, 48 and 72 h with culture medium alone (control) or with 100, 500 and 1000 μg/ml of pirfenidone with or without 0.1, 1, 5, 10 ng/ml of TGF-β1. Changes in cell morphology were also assessed under phase contrast light microscopy.
RNA extraction and reverse-transcriptase PCR
Total RNA was isolated from the cells using the Qiagen RNeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. Samples were digested with DNase I (Qiagen) to remove contaminating genomic DNA. Isolated total RNA was analyzed using a DU 800 UV/Visible Spectrophotometer (Beckman Coulter, Fullerton, CA). To generate complementary DNA (cDNA), total RNA (5 μg) was reverse-transcribed using the SuperScriptTM III first strand synthesis kit (Invitrogen, Carlsbad, CA) with oligo deoxythymidine as a primer. The reverse transcriptase reaction proceeded in a total volume of 20 μl in a Gene Amp PCR system 9700 (Applied Biosystems, Foster City, CA) at 65 °C for 5 minutes, followed by 50 minutes at 42 °C and 15 minutes at 70 °C. Reaction volumes of 25 μl were placed in 96-well optical reaction plates with adhesive covers (ABI PrismTM Applied Biosystems) using TaqManTM Universal PCR Master Mix (Applied Biosystems). Human beta-actin (β-actin) served as the internal control. TaqMan probes for human E-cadherin and β-actin were purchased from Applied Biosystems. Samples were heated to 95 °C for 10 min and then PCR amplification was achieved by 40 cycles at 95 °C for 15 s and at 60 °C for 1 min using the ABI Prism 7500 (Applied Biosystems) as described by the manufacturer. Real-time data were analyzed using the comparative CT method, where CT is the cycle number at which the fluorescence reading is first recorded above background levels. The comparative CT and standard curve methods are similar except the former uses the arithmetic formula, 2–ΔΔCT to achieve relative quantification. A prior validation experiment demonstrated that amplification efficiencies of the primer/probe sets of the target genes and β-actin were approximately equal and within 0.1.
Samples were Northern blotted for collagen type I and HSP47 as described [20, 29]. Human HSP47 and collagen-type I complementary DNAs (cDNAs) were provided by the Institute for Frontier Medical Science, Kyoto University, Japan. HSP47 mRNA was detected using a 1.5 kilobase pair (kbp) EcoRI fragment of full-length human HSP47 (CBP2) cDNA as a probe, whereas collagen type I mRNA was detected using a 0.6 kbp EcoRV fragment of full-length pCOLA1-I-CP cDNA as a probe. The probes were labeled with 32P using a Random Primer Labeling kit (Takara Biomedicals, Shiga, Japan). Isolated RNAs (10 μg) were resolved by electrophoresis on 1% agarose gels containing 1.2% formaldehyde, transferred to a nylon membrane (HybondTM-N+, Amersham International, Amersham, UK), and then separately hybridized with each 32P-labeled probe for 24 h at 42 °C. Autoradiographed membranes were assessed using a BAS5000 Bioimage Analyzer (Fuji Photo Film, Japan). Relative transcription was normalized against hybridization with a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe.
After a 48-h incubation as detailed above, cultured cells were fixed with acetone for 10 min and stained using the alkaline phosphatase anti-alkaline phosphatase method with goat anti-human collagen type I polyclonal (CHEMICON, Temecula, CA), mouse anti-human HSP47 (Stressgen, Victoria, Canada) and mouse anti-cellular fibronectin monoclonal (CHEMICON) antibodies. Negative controls included an irrelevant mouse or goat IgG (Santa Cruz Biotechnology, Santa Cruz, CA). The staining intensity of collagen type I and HSP47 in A549 cells was semi-quantified at × 400 magnification in five fields using a grading score of 0 to 3 (0, 1, 2 and 3, corresponding to absent, weak, moderate and intense staining, respectively). The total cell count was converted to 100, so the maximum number was 300 in this scoring system. The interobserver and intraobserver variability in assessing the results was reproducible. Representative results from one observer were statistically analyzed.
All values are expressed as means ± SEM. The minimum number of replicates for all measurements was at least 3. Differences between multiple groups were compared by one-way analysis of variance. Dunnett's test served as the post hoc test for multiple comparisons. Significance was assumed at p < 0.05.
TGF-β1 enhances the expression of collagen type I and HSP47 mRNA and protein in A549 cells
We first determined the time course of the TGF-β1 (5 ng/ml) effect on the mRNA expression of collagen type I and HSP47 in A549 cells. The response of collagen type I to 5 ng/ml of TGF-β1 was maximal after 6, 12, 24 and 72 h of incubation (Figure 1a). TGF-β1 at 5 and 10 ng/ml also significantly increased the expression of collagen type I mRNA after 6 h of incubation (Figure 1b). The response of HSP47 to 5 ng/ml TGF-β1 was maximal after 48 and 72 h of incubation (Figure 1c). Figure 1d shows that TGF-β1 at 5 and 10 ng/ml significantly increased HSP47 mRNA expression compared with untreated controls after 48 h. We next examined the effects of TGF-β1 on collagen type I and HSP47 protein expression in A549 cells using immunocytochemical staining. We found that 1, 5 and 10 ng/ml of TGF-β1 increased the number of cells that were immunopositive for both collagen type I and HSP47 at 48 h (Figure 2).
Effects of pirfenidone on production of collagen type I and HSP47 in TGF-β1-stimulated A549 cells
The effect of pirfenidone on TGF-β1-induced expression of collagen type I and HSP47 mRNA in A549 cells was analysed by Northern blotting (Figure 3). Incubation with 500 and 1000 μg/ml of pirfenidone induced significant downregulation of collagen type I (6 h) and of HSP47 (48 h) mRNA expression in A549 cells stimulated by TGF-β1 at 5 ng/ml. Figure 4 shows the immunocytochemical findings obtained using the anti-human collagen type I and HSP47 antibodies. Pirfenidone significantly decreased the numbers of collagen type I- and HSP47-immunopositive cells at 100, 500 and 1000 μg/ml, and at 500 and 1000 μg/ml, respectively.
Effects of pirfenidone on EMT in TGF-β1-stimulated A549 cells
Immunocytochemical staining of A549 cells showed that pirfenidone inhibited the TGF-β1-induced over-expression of fibronectin, which is a mesenchymal phenotypic marker (Figure 5a-d). Loss of the epithelial marker E-cadherin mRNA in A549 cells induced by TGF-β1 was also normalized by pirfenidone, but this difference did not reach significance (Figure 5e). In addition to the changes in the phenotypic markers, changes in cell morphology were also assessed under phase contrast light microscopy. Untreated A549 cells show a pebble-like epithelial shape and TGF-β1-treated cells show a spindle-like mesenchymal shape. Pirfenidone partially suppressed TGF-β1-induced mesenchymal morphology (Figure 6).
The major finding of the present study was that TGF-β1 enhanced HSP47 and collagen type I synthesis in A549 cells at both the mRNA and protein levels and that pirfenidone directly inhibited these effects.
The collagen-binding, stress-inducible protein, HSP47, acts as a collagen-specific molecular chaperone in the intracellular processing of procollagen [21–23]. In a murine model of bleomycin-induced pulmonary lung fibrosis, HSP47 mRNA and protein expression predominantly increased in α-SMA-positive myofibroblasts of the lung interstitium, and the relative amounts of HSP47 mRNA in the lung significantly correlated with the hydroxyproline content [12, 27]. In addition to fibroblasts, type II pneumocytes in this mouse model expressed HSP47, suggesting that type II pneumocytes also contribute to lung fibrosis . The expression of type I procollagen and HSP47 was also significantly higher in type II pneumocytes identified in surgical biopsy specimens from patients with idiopathic usual interstitial pneumonia (UIP) than in those from patients with collagen vascular disease-associated UIP and idiopathic nonspecific interstitial pneumonia , which have better prognoses than idiopathic UIP . These findings suggest that in addition to fibroblasts, type II pneumocytes also directly contribute to lung fibrosis thorough collagen and HSP47 synthesis.
Pirfenidone exerts both anti-inflammatory and anti-fibrotic activities in animal models of pulmonary fibrosis induced by bleomycin [9–12] and cyclophosphamide . These studies in vivo showed that pirfenidone obviously reduced the histological and biochemical signs of lung fibrosis including the hydroxyproline content. Pirfenidone also decreased the levels of pulmonary protein and gene expression of some fibrogenic cytokines such as TGF-β1  and platelet-derived growth factor (PDGF) . Our recent study in vitro showed that pirfenidone directly inhibits collagen type I and HSP47 expression in TGF-β1-stimulated human lung fibroblasts . Together, these findings indicate the potential of pirfenidone as a novel, broad-spectrum anti-fibrotic agent. In addition, pirfenidone suppresses the increased expression of HSP47 in our mouse model of lung fibrosis , suggesting that this drug could change the fibroblast phenotype. Here, we demonstrated a similar inhibitory effect of pirfenidone on collagen type I and HSP47 in A549 cells at both the protein and mRNA levels in vitro, confirming that the effect of pirfenidone on collagen and HSP47 in vivo represented a direct effect on type II pneumocytes. In addition to its anti-inflammatory action, pirfenidone might act as an anti-fibrotic agent for patients with IPF by directly inhibiting HSP47 and collagen production in type II pneumocytes as well as in fibroblasts in the human lung. In this context, our immunocytochemical study of collagen I showed that pirfenidone co-administration significantly reduced the ratio (%) of positive cells at 100 μg/ml and significantly inhibited TGF-β1-enhanced HSP47 and collagen type I mRNA expression at 500 μg/ml. This suggests that pirfenidone acts as an anti-fibrotic agent by directly inhibiting both HSP47 and collagen type I mRNA expression, which results in reduced collagen synthesis in type II pneumocytes. In support of this proposal, HSP47 inhibition by antisense oligodeoxynucleotides obviously suppresses collagen production in 3 T6 cells , experimental proliferative glomerulonephritis  and in peritoneal fibrosis , indicating that HSP47 is a promising target for the treatment of fibrotic diseases including IPF. This study thus identified pirfenidone as the first known agent that can control HSP47 and collagen expression in type II pneumocytes.
Recent evidence from studies of pulmonary fibrosis supports the role of EMT in the development of fibroblastic foci in IPF . Yao and colleagues  showed that TGF-β1 induces EMT in alveolar epithelial cells from SD rats. Kasai and colleagues also reported that TGF-β1, but not TNF-α or interleukin-1β, induced A549 cells to undergo EMT . Willis and colleagues also demonstrated that cultures of primary rat alveolar epithelial cells and a rat alveolar epithelial cell line undergo EMT in response to TGF-β1 stimulation . Kim et al. also reported that the main source of mesenchymal expansion is lung epithelial cells from a mouse model of pulmonary fibrosis in vivo. The induction of EMT is characterized by the expression of α-SMA, transformation of myofibroblast morphology, the increased formation of stress fibers by F-actin reorganization, and loss of the epithelial marker E-cadherin. Collagen type I and HSP47 expression is also considered to be one of the useful parameters for recognizing EMT . These recent findings and our present data demonstrate that EMT develops in alveolar epithelial cells mediated by TGF-β1, suggesting that such development represents an important mechanism of myofibroblast production during pulmonary fibrosis. In addition, the present data showed that the over-expression of collagen type I, HSP47 and fibronectin induced by TGF-β1 in A549 cells was inhibited by pirfenidone. TGF-β1-induced loss of E-cadherin in A549 cells was also normalized by pirfenidone while this difference was not significant. In addition, pirfenidone inhibited a mesenchymal morphology induced by TGF-β1. These suggest that pirfenidone might partially inhibit EMT.
The anti-fibrotic effects of pirfenidone might be mediated not only through the direct inhibition of collagen type I expression but also through the inhibition of HSP47 expression in alveolar epithelial cells, which results in reduced collagen synthesis in lung fibrosis. Furthermore, pirfenidone might partially inhibit the epithelial-mesenchymal transition.
Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, Travis WD, Flint A, Toews GB, Lynch JP, et al: Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003, 168 (5): 543-548. 10.1164/rccm.200209-1112OC.
Willis BC, DuBois RM, Borok Z: Epithelial origin of myofibroblasts during fibrosis in the lung. Proc Am Thorac Soc. 2006, 3 (4)): 377-382.
Kasai H, Allen JT, Mason RM, Kamimura T, Zhang Z: TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res. 2005, 6: 56-10.1186/1465-9921-6-56.
Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, Brumwell AN, Sheppard D, Chapman HA: Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA. 2006, 103 (35): 13180-13185. 10.1073/pnas.0605669103.
Willis BC, Liebler JM, Luby-Phelps K, Nicholson AG, Crandall ED, du Bois RM, Borok Z: Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol. 2005, 166 (5): 1321-1332. 10.1016/S0002-9440(10)62351-6.
Selman M, Pardo A: Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc. 2006, 3 (4): 364-372. 10.1513/pats.200601-003TK.
Di Sario A, Bendia E, Macarri G, Candelaresi C, Taffetani S, Marzioni M, Omenetti A, De Minicis S, Trozzi L, Benedetti A: The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2. Dig Liver Dis. 2004, 36 (11): 744-751. 10.1016/j.dld.2004.05.012.
Hewitson TD, Kelynack KJ, Tait MG, Martic M, Jones CL, Margolin SB, Becker GJ: Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. J Nephrol. 2001, 14 (6): 453-460.
Iyer SN, Margolin SB, Hyde DM, Giri SN: Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model. Exp Lung Res. 1998, 24 (1): 119-132. 10.3109/01902149809046058.
Iyer SN, Gurujeyalakshmi G, Giri SN: Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther. 1999, 291 (1): 367-373.
Iyer SN, Hyde DM, Giri SN: Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation. 2000, 24 (5): 477-491. 10.1023/A:1007068313370.
Kakugawa T, Mukae H, Hayashi T, Ishii H, Abe K, Fujii T, Oku H, Miyazaki M, Kadota J, Kohno S: Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. Eur Respir J. 2004, 24 (1): 57-65. 10.1183/09031936.04.00120803.
Kehrer JP, Margolin SB: Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice. Toxicol Lett. 1997, 90 (2–3): 125-132.
Gurujeyalakshmi G, Hollinger MA, Giri SN: Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol. 1999, 276 (2 Pt 1): L311-L318.
Nakazato H, Oku H, Yamane S, Tsuruta Y, Suzuki R: A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol. 2002, 446 (1–3): 177-185.
Oku H, Nakazato H, Horikawa T, Tsuruta Y, Suzuki R: Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol. 2002, 446 (1–3): 167-176.
Raghu G, Johnson WC, Lockhart D, Mageto Y: Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med. 1999, 159 (4 Pt 1): 1061-1069.
Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, et al: Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005, 171 (9): 1040-1047. 10.1164/rccm.200404-571OC.
Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, et al: Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010, 35 (4): 821-829. 10.1183/09031936.00005209.
Nakayama S, Mukae H, Sakamoto N, Kakugawa T, Yoshioka S, Soda H, Oku H, Urata Y, Kondo T, Kubota H, et al: Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts. Life Sci. 2008, 82 (3–4): 210-217.
Ishida Y, Kubota H, Yamamoto A, Kitamura A, Bachinger HP, Nagata K: Type I collagen in Hsp47-null cells is aggregated in endoplasmic reticulum and deficient in N-propeptide processing and fibrillogenesis. Mol Biol Cell. 2006, 17 (5): 2346-2355. 10.1091/mbc.E05-11-1065.
Saga S, Nagata K, Chen WT, Yamada KM: pH-dependent function, purification, and intracellular location of a major collagen-binding glycoprotein. J Cell Biol. 1987, 105 (1): 517-527. 10.1083/jcb.105.1.517.
Sauk JJ, Smith T, Norris K, Ferreira L: Hsp47 and the translation-translocation machinery cooperate in the production of alpha 1(I) chains of type I procollagen. J Biol Chem. 1994, 269 (6): 3941-3946.
Abe K, Ozono Y, Miyazaki M, Koji T, Shioshita K, Furusu A, Tsukasaki S, Matsuya F, Hosokawa N, Harada T, et al: Interstitial expression of heat shock protein 47 and alpha-smooth muscle actin in renal allograft failure. Nephrol Dial Transplant. 2000, 15 (4): 529-535. 10.1093/ndt/15.4.529.
Shioshita K, Miyazaki M, Ozono Y, Abe K, Taura K, Harada T, Koji T, Taguchi T, Kohno S: Expression of heat shock proteins 47 and 70 in the peritoneum of patients on continuous ambulatory peritoneal dialysis. Kidney Int. 2000, 57 (2): 619-631. 10.1046/j.1523-1755.2000.00883.x.
Kakugawa T, Mukae H, Hayashi T, Ishii H, Nakayama S, Sakamoto N, Yoshioka S, Sugiyama K, Mine M, Mizuta Y, et al: Expression of HSP47 in usual interstitial pneumonia and nonspecific interstitial pneumonia. Respir Res. 2005, 6: 57-10.1186/1465-9921-6-57.
Ishii H, Mukae H, Kakugawa T, Iwashita T, Kaida H, Fujii T, Hayashi T, Kadota J, Kohno S: Increased expression of collagen-binding heat shock protein 47 in murine bleomycin-induced pneumopathy. Am J Physiol Lung Cell Mol Physiol. 2003, 285 (4): L957-L963.
Zeisberg M, Neilson EG: Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009, 119 (6): 1429-1437. 10.1172/JCI36183.
Yoshioka S, Mukae H, Ishii H, Kakugawa T, Ishimoto H, Sakamoto N, Fujii T, Urata Y, Kondo T, Kubota H, et al: Alpha-defensin enhances expression of HSP47 and collagen-1 in human lung fibroblasts. Life Sci. 2007, 80 (20): 1839-1845. 10.1016/j.lfs.2007.02.014.
Park JH, Kim DS, Park IN, Jang SJ, Kitaichi M, Nicholson AG, Colby TV: Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med. 2007, 175 (7): 705-711. 10.1164/rccm.200607-912OC.
Sunamoto M, Kuze K, Tsuji H, Ohishi N, Yagi K, Nagata K, Kita T, Doi T: Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress collagen accumulation in experimental glomerulonephritis. Lab Invest. 1998, 78 (8): 967-972.
Nishino T, Miyazaki M, Abe K, Furusu A, Mishima Y, Harada T, Ozono Y, Koji T, Kohno S: Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress peritoneal fibrosis in rats. Kidney Int. 2003, 64 (3): 887-896. 10.1046/j.1523-1755.2003.00169.x.
Yao HW, Xie QM, Chen JQ, Deng YM, Tang HF: TGF-beta1 induces alveolar epithelial to mesenchymal transition in vitro. Life Sci. 2004, 76 (1): 29-37. 10.1016/j.lfs.2004.06.019.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2466/12/24/prepub
The authors thank Mr. Atsushi Yokoyama (Nagasaki University Hospital) for excellent technical assistance. This study was supported in part by KAKENHI.
The authors alone are responsible for the content and writing of the paper. HO is an employee of Shionogi & Co.,Ltd. SK received manuscript fee and consultant from Shionogi & Co.,Ltd.
KH wrote manuscript and did laboratory work, TK, SH, HF, SN, and YU did laboratory work, NS, YI, HO, HK, and KN did study design and assisted manuscript-writing, HM, SK supervised all the experiment and manuscript-writing. All authors read and approved the final manuscript.